Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Krieg

Showing results (571-580 of 647) with videos related to

Pageof 65
Sort By:
Veterinary Immunology and Immunopathology|December 30, 2006
Systemic innate immune responses following intrapulmonary delivery of CpG oligodeoxynucleotides in sheepAnil K Nichani, M Arshud Dar, Arthur M Krieg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 21, 2000
Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivoG Hartmann, R D Weeratna, Z K Ballas, et al.
Neuro-Oncology Advances|April 10, 2026
Tumor recurrence patterns in eloquent glioma after microsurgical resection and adjuvant radiochemotherapyMaximilian Schwendner, Stefan Suvak, Sarah Stefanowicz, et al.
Cellular Immunology|March 13, 2008
Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligandsJeffrey A Martinson, Alejandro Roman-Gonzalez, Allan R Tenorio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphomaJohn P Leonard, Brian K Link, Christos Emmanouilides, et al.
Journal of Clinical Pharmacology|January 5, 2002
Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjectsH Möllmann, M Wagner, S Krishnaswami, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 20, 2006
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor siteVictor Appay, Camilla Jandus, Verena Voelter, et al.
Journal of Neuro-Oncology|June 11, 2026
Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults - a retrospective, single institute experienceFabian J K Allmendinger, Maximilian Deng, Sebastian Regnery, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 17, 2012
Lipid-derived nanoparticles for immunostimulatory RNA adjuvant deliveryDavid N Nguyen, Kerry P Mahon, Ghania Chikh, et al.
BMJ Open|September 11, 2024
Resection versus biopsy in patients with glioblastoma (RESBIOP study): study protocol for an international multicentre prospective cohort study (ENCRAM 2202)Jasper Kees Wim Gerritsen, Jacob S Young, Sandro M Krieg, et al.
Pageof 65

Showing results (571-580 of 647) with videos related to

Sort By:
Pageof 65
Veterinary Immunology and Immunopathology|December 30, 2006
Systemic innate immune responses following intrapulmonary delivery of CpG oligodeoxynucleotides in sheepAnil K Nichani, M Arshud Dar, Arthur M Krieg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 21, 2000
Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivoG Hartmann, R D Weeratna, Z K Ballas, et al.
Neuro-Oncology Advances|April 10, 2026
Tumor recurrence patterns in eloquent glioma after microsurgical resection and adjuvant radiochemotherapyMaximilian Schwendner, Stefan Suvak, Sarah Stefanowicz, et al.
Cellular Immunology|March 13, 2008
Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligandsJeffrey A Martinson, Alejandro Roman-Gonzalez, Allan R Tenorio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphomaJohn P Leonard, Brian K Link, Christos Emmanouilides, et al.
Journal of Clinical Pharmacology|January 5, 2002
Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjectsH Möllmann, M Wagner, S Krishnaswami, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 20, 2006
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor siteVictor Appay, Camilla Jandus, Verena Voelter, et al.
Journal of Neuro-Oncology|June 11, 2026
Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults - a retrospective, single institute experienceFabian J K Allmendinger, Maximilian Deng, Sebastian Regnery, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 17, 2012
Lipid-derived nanoparticles for immunostimulatory RNA adjuvant deliveryDavid N Nguyen, Kerry P Mahon, Ghania Chikh, et al.
BMJ Open|September 11, 2024
Resection versus biopsy in patients with glioblastoma (RESBIOP study): study protocol for an international multicentre prospective cohort study (ENCRAM 2202)Jasper Kees Wim Gerritsen, Jacob S Young, Sandro M Krieg, et al.
Pageof 65